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Beijing has been one of the epicenters attacked most severely by the SARS-CoV
(severe acute respiratory syndrome-associated coronavirus) since the ﬁrst patient
was diagnosed in one of the city’s hospitals. We now report complete genome
sequences of the BJ Group, including four isolates (Isolates BJ01, BJ02, BJ03,
and BJ04) of the SARS-CoV. It is remarkable that all members of the BJ Group
share a common haplotype, consisting of seven loci that diﬀerentiate the group
from other isolates published to date. Among 42 substitutions uniquely identi-
ﬁed from the BJ group, 32 are non-synonymous changes at the amino acid level.
Rooted phylogenetic trees, proposed on the basis of haplotypes and other sequence
variations of SARS-CoV isolates from Canada, USA, Singapore, and China, gave
rise to diﬀerent paradigms but positioned the BJ Group, together with the newly
discovered GD01 (GD-Ins29) in the same clade, followed by the H-U Group (from
Hong Kong to USA) and the H-T Group (from Hong Kong to Toronto), leaving
the SP Group (Singapore) more distant. This result appears to suggest a possible
transmission path from Guangdong to Beijing/Hong Kong, then to other countries
and regions.
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China is the prime victim of the sudden outbreak of
SARS (severe acute respiratory syndrome) due to a
newly identiﬁed variant of coronavirus, the SARS-
CoV (1). Beijing metropolitan area is one of the epi-
centers that have been severely attacked by the virus
since its ﬁrst patient was identiﬁed on March 1, 2003.
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Both the numbers of cases and of deaths of SARS in
Beijing alone were accounted for 29.92% and 23.57%,
respectively, of those in the entire world up to June
10, 2003 (Figure 1). We have been working on se-
quencing SARS-CoV genomes from clinical isolates
since early April of this year and have released our
data as soon as we acquired them. We now report our
detailed comparative analyses on a group of four com-
plete genome sequences (Isolates BJ01, BJ02, BJ03,
and BJ04), named the BJ Group, by referencing the
thirteen SARS-CoV genome sequences in the public
databases (2-4).
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Fig. 1 Accumulated number of probable cases and deaths of SARS in Beijing, China, and the world. Data sources:
http://www.moh.gov.cn/zhgl/yqfb/index.htm; http://www.who.int/csr/sars/country/en/.
SARS Patients, SARS-CoV Iso-
lates and Genome Sequencing
SARS patients were clinically diagnosed in March
2003 according to World Health Organization (WHO)
guidelines (http://www.who.int/csr/sars/guidelines
/en/). SARS-CoV isolates were maintained in Vero-
6 cell cultures that were inoculated from autopsies
and biopsies of the deceased or recovered SARS pa-
tients (Table 1). Viral RNA was puriﬁed from virions
prepared from the cultures and subjected for cDNA
syntheses. A set of primers that cover the entire viral
genome were used for the reverse transcription and
PCR ampliﬁcation, in a product size range of 400-800
bp. PCR-ampliﬁed fragments were then cloned into
amplicon-libraries and two dozens or more clones were
sequenced for each PCR-ampliﬁed fragments to en-
sure sequence quality and to avoid errors in the proce-
dures of the RT-PCR and cloning. Only the consensus
sequences with absolute majority votes were used for
the genome assembly and gene annotation, although
every read was assembled and some sequence varia-
tions were clearly visible. For comparative genomic
analyses, 13 other full-length SARS-CoV genome se-
quences were downloaded from GenBank (Table 2;
http://www.ncbi.nlm.nih.gov). The nucleotide posi-
tions of Isolate BJ01 were used as the reference for
analyses.
Table 1 Samples and Clinical Data for the BJ Group (Isolates BJ01-BJ04)
Isolate GenBank Tissue Sample Clinical outcome
accession number
BJ01 AY278488 Lung Autopsy Deceased
BJ02 AY278487 Nose & throat Swabs (mixed patients infected by BJ01) Recovered
BJ03 AY278490 Liver & lymph nodes Autopsy (same as BJ01) Deceased
BJ04 AY279354 Lung Autopsy Deceased
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Table 2 Information Summary of the Complete Genome Sequences of the BJ Group
and Other 13 Isolates of SARS-CoV*
Isolate Genome size (nt) Accession number Modiﬁcation date
BJ01 29,725 AY278488.2 1-May-03
BJ02 29,745 AY278487 5-June-03
BJ03 29,740 AY278490 5-June-03
BJ04 29,732 AY279354 29-May-03
GD01 29,757 AY278489 29-May-03
ZJ01 29,715 AY297028.1 19-May-03
TW1 29,729 AY291451.1 14-May-03
CUHK-W1 29,736 AY278554.2 14-May-03
CUHK-Su10 29,736 AY282752.1 7-May-03
Urbani 29,727 AY278741.1 21-Apr-03
HKU-39849 29,742 AY278491.2 18-Apr-03
TOR2 29,751 NC 004718.3 22-May-03
SIN2500 29,711 AY283794.1 9-May-03
SIN2677 29,705 AY283795.1 9-May-03
SIN2679 29,711 AY283796.1 9-May-03
SIN2748 29,706 AY283797.1 9-May-03
SIN2774 29,711 AY283798.1 9-May-03
*Data were retrieved from GenBank: http://www.ncbi.nlm.nih.gov.
Isolates BJ01 and BJ03 were derived from the
autopsied lung tissue (BJ01) and liver/lymph nodes
(BJ03) of the same patient who was the father of the
ﬁrst patient (the Index Case of Beijing) diagnosed on
March 1, 2003 in Beijing. His own daughter infected
him in the last week of February in Shanxi Province
after she traveled to Guangdong Province during the
period of February 18th to 23rd. He was 53 years old
and had no detectable symptoms of hepatitis, AIDS,
or heart diseases. He, as the second SARS patient hos-
pitalized (March 5th) in Beijing, died two days after
the diagnosis. His daughter, however, had recovered
completely from the horrifying ordeal after medical
treatments. The sequence diﬀerences between Isolates
BJ01 and BJ03 are expected to reﬂect the sequence
variations within the same patient after viral infec-
tion. Isolate BJ02 was inoculated from pooled sam-
ples of nose/throat swabs from seven patients who
were all evidenced to be infected by the ﬁrst patient
when she (the Index Case of Beijing) was hospitalized
in the ﬁrst week of March at the same hospital. All
of these patients were recovered after eﬀective treat-
ments. The sequence diﬀerences between BJ01 and
BJ02 should be regarded as the variation from the
ﬁrst circle or round of the infection. Isolate BJ04 was
inoculated from the autopsied lung tissue of a sin-
gle deceased patient who had no direct contact with
the Index Case of Beijing. The sequence diﬀerences
between BJ04 and other BJ cases should yield vari-
ations during viral infections outside the ﬁrst circle.
As a whole, the group of isolates, or the BJ Group,
represents the early rounds of disease transmissions in
Beijing. Another relevant case concerns Isolate GD01
(previously named GZ01). It was isolated from the
autopsied lung tissue of a single deceased patient who
was a female of 54 years old. She was suspected being
infected during her hospitalization by indirect contact
with one of the “superspreaders”, who stayed in the
same hospital as she did. She was one of the SARS
cases with known transmission path connecting to the
“Index Cases” identiﬁed in Guangdong Province. Its
genome sequence serves as a root or an anchor point
for the BJ Group. In addition, the genome sequence of
GD01 harbors a 29-nt insertion, a rare genotype so far
only found in the samples from Guangdong Province
(5).
The sequences of the four complete genomes have
a size range of 29,725-29,745 nucleotides (nt). The
diﬀerence is primarily due to the extension of the
5′-end sequence, which has no signiﬁcant changes in
the overall genome structure and gene size. In the
genomes of these isolates, the predicted number of
ORFs (open reading frames) remains as 13, in con-
trast to the genome of Isolate GD01, where a 29-
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nt insertion was discovered. Sequence evidence from
another SARS-CoV isolate collected in Guangdong
has conﬁrmed this signiﬁcant ﬁnding (BGI unpub-
lished data). Referring to the BJ01 genome annota-
tion, we have previously reported that, in the GD01
genome, two additional BGI-PUPs (BGI-Postulated
Uncharacterized Proteins), BGI-PUP5 (nt positions
27,763-27,882) and BGI-PUP6 (nt positions 27,848-
28,102), were predicted in the largest (478 nt) in-
tergenic region between the ORFs for BGI-PUP4
and the N protein (nucleoprotein); PUP5 was pre-
viously so named in BJ01 and now renamed as
BGI-PUP7. Putative leader sequences were deter-
mined in these genomes, based on alignments of the
leader sequence at the 5′-end of the genome (5′-
UCUCUAAACGAACUUUAAAAUCUG) to the se-
quences upstream of each ORF. The organization and
general features of viral proteins, including the R
(replicase) protein and the structural proteins (the
spike or S, envelope or E, membrane or M, and N
proteins), among all the isolates are nearly identical
except the 29-nt insertion in the GD isolates and the
limited number of nucleotide substitutions.
A Novel Haplotype Found
Unique to the BJ Group
A salient discovery in our study is that all members
of the BJ Group share a common haplotype of 7 loci,
C/t-T-G-C-A-C-G-C-T-C (letters in uppercases indi-
cate the major allele at the locus and letters in low-
ercases specify the minor allele; Table 3); a new mu-
tation occurred in BJ04 at Locus 9,385 is responsible
for the minor allele t. Isolate BJ04, which was har-
bored by a patient who did not have any direct con-
tacts with the other BJ cases, is clustered with most
members of the other groups. If GD01 is included in
the group, the haplotype remains as C/t-T/c-G-C-A-
C-G-C-T-C ; it introduces another minor allele c at
Locus 9,835. Even if we exclude either BJ01 or BJ03,
the two isolates from a single patient, the haplotype
still stands out; it has diﬀerentiated the group from
all other isolates (T/c-C-T/g-C/t-A/g-C/t-A-T/c-C-
T/c) identiﬁed so far. This BJ Group-speciﬁc hap-
lotype represents the ﬁrst population of SARS-CoV
responsible for the acute outbreak in the metropoli-
tan area of Beijing.
Table 3 The Group-Specific Haplotypes of SARS-CoV
BJGroup H-U Group H-T Group SP Group
ORF Locusa BJ01 BJ02 BJ03 BJ04 GD01 CUHKCUHKUrbani HKU TOR2 ZJ01 TW1 SIN SIN SIN SIN SIN
-W1 -Su10 -39849 2679 2748 2774 2500 2677
9,385 Cb C C t C c T T T T T T T T T T T
9,835 T T T T c C C C C C C C C C C C C
17,545 G G G G G g T T T T T T T T T T T
R 17,827 C C C C C T T c C C C C C C C C C
19,045 A A A A A G a G A A A A A A A A A
19,065 C C C C C C C C C C C C c T T T T
19,819 G G G G G A A A A A A A A A A A A
S 22,203 C C C C C c T T T T T T T T T T T
BGI-PUP3 27,224 T T T T T C C C C C C C C C C C C
BGI-PUP5 27,808 C C C C C c T T T T T T T T T T T
aA locus is deﬁned by the nucleotide position with reference to the complete genome sequence of BJ01.
bCapital letters indicate the major allele with the highest frequency at the locus within the corresponding group, and
low-case letters denote the minor allele. Shaded areas highlight the possible haplotypes.
The H-U Group (from Hong Kong to USA) has
a diﬀerent haplotype, T/c-C-T/g-T/c-G/a-C-A-T/c-
C-T/c. The major allele T within the group at Locus
17,827 that is shared by CUHK-W1 and CUHK-Su10,
together with the major allele G at Locus 19,045
shared by CUHK-W1 and Urbani (named after Dr.
Carlo Urbani who was the ﬁrst WHO oﬃcer to iden-
tify the outbreak of this new disease in an Ameri-
can businessman who had been admitted to a hospital
in Hanoi), establishes the internal association within
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the H-U Group. The fact that the H-U Group over-
laps with the BJ Group by Isolate CUHK-W1 (c-C-
g-T-G-C-A-c-C-c) suggests a possible link or path of
transmission between the BJ and H-U Groups. The
H-U Group appears to be a mosaic genotype of the
BJ and other groups. The result suggests the ex-
istence of an intermediate state in the transmission
path connecting China to the outside. In addition to
the haplotype, T-C-T-C-A-T-A-T-C-T, identical to
the H-T Group (from Hong Kong to Toronto) as well
as Isolates ZJ01 (Zhejiang) and TW1 (Taiwan), the
SP Group (Singapore) possesses a monolocus marker
T, as opposed to C for all others at Locus 19,065,
thus establishing the internal phylogenetic relation-
ship within the group and diﬀerentiating it from all
others. GD01 shares an almost identical haplotype
with the BJ Group at the deﬁned loci, except for the
minor allele c at Locus 9,835, which distances itself
from the BJ Group but links it to all the other groups.
Sequence Variations in the BJ
Group in Comparison with other
Isolates
137 sequence variations (142 if counted independently
by each ORF) were deﬁned by comparing the se-
quences of the BJ Group with other isolates, including
3 (GD01, ZJ01, and TW1) identiﬁed in China, and 10
others elsewhere (Figure 2, Table 4). Out of the total,
42 were contributed by the BJ Group alone, amount-
ing to nearly 30% of the grand total. These varia-
tions were conﬁrmed among over a dozen high-quality
sequence reads from re-sequencing of the RT-PCR
products directly and clones from the correspond-
ing amplicon-derived libraries. Although possible se-
quence variations acquired during the limited gener-
ations in the host body and viral culture as well as
sequencing errors arisen from the RT-PCR and ampli-
ﬁcation/cloning could not be easily excluded, the like-
lihood that all BJ isolates mutate in a similar way is
rather slim since the sequencing was done in a system-
atic way with overlapping segments and high quality.
The quality of complete genome sequences from other
contributors was assessed by manually checking the
submitted sequence traces when publicly available. In
the substitutions identiﬁed from the BJ group, 76%
are categorized as non-synonymous, slightly higher
than the average (70%, 100/142) calculated from all
17 isolates. As a benchmark, we have summarized
a few commonly used parameters for viral evolution
studies together with those of two other RNA viruses,
the HIV-1 and inﬂuenza (Table 5). The SARS-CoV
in many ways is quite diﬀerent from these two viruses,
except that their genomes are all RNA in nature. In
particular, the HIV lives with the host for a long time
so the constant escape from the host immune system
is of essence for its survival until it overwhelms the
system (6). The inﬂuenza virus that has an 85-year
recorded history of infecting humans causes recurrent
annual epidemics until a novel virus rises to stir up
major worldwide pandemics (7). Our results did not
lead to any strong conclusions due to insuﬃcient data
points compared to both HIV and inﬂuenza but it is
quite necessary to compare the SARS-CoV data with
those of the two prevalent viruses from time to time.
Aside from mutation rate calculations, a popular test
for selection on a particular protein is the ratio of
Ka/Ks (8). Generally, most non-synonymous SNPs
(single nucleotide polymorphisms) are believed to be
deleterious and rapidly removed from the given popu-
lation of viruses by selection, leaving Ka/Ks less than
one. Conversely, Ka/Ks greater than one is a strong
indicator of positive selection. Although we have seen
a high ratio in the case of PUP2, the indication of such
a number from an uncharacterized putative transcript
remains to be elucidated. At the present time, lim-
ited by the amount of experimental data, the ratio
of Ka/Ks in the SARS-CoV data is higher than that
of most genes in HIV and inﬂuenza viruses, in which
selection and adaptation are both playing signiﬁcant
roles in changing the rate of non-synonymous substi-
tutions, especially for the structural proteins that are
the targets of the host immune systems.
Instead, we have inspected these substitutions in-
dividually to the nucleotide positions in a context of
a codon. It is not surprising to ﬁnd that the three-
nucleotide positions within a codon have a similar
frequency to be mutated when insuﬃcient evolution-
ary processes are yet to be experienced by the newly
emerged virus. Among all the 139 substitutions (in-
cluding 2 counted in 2 ORFs), 45 are at the ﬁrst nu-
cleotide position, 47 are at the second one, and 47 are
at the third one. It implies that the selective pres-
sure has yet to work on these mutations that were
most likely generated in the initial viral population
due to replication errors of the viral machinery. Many
interesting non-synonymous substitutions were found
among the group. A common A/C transversion (Lo-
cus 26,031, C in both BJ01 and BJ03, A in all other
isolates, including two of the BJ Group, BJ02 and
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Fig. 2 Distribution of the non-synonymous substitutions in the SARS-CoV genome from the known cases. The tall
vertical bars represent the substitutions detected from the BJ Group and the low bars denote those from non-BJ
Groups. The scale marks the nucleotide positions in reference to BJ01.
Table 4 Summarized Substitutions Identified in the BJ Group and other 13 Isolates of SARS-CoV
ORF Size(nt) No.of S* Percentage of substitutions (%) No. of N-Syn* Percentage of N-Syn (%)
BJ Group All BJ Group All BJ Group All BJ Group All
R 21,222 25 92 0.12 0.43 21 65 84 71
S 3,768 9 22 0.24 0.58 6 13 67 59
BGI-PUP1 825 4 9 0.48 1.09 2 6 50 67
BGI-PUP2 465 2 5 0.43 1.08 2 4 100 80
E 231 0 1 0 0.43 0 1 100
M 666 0 4 0 0.60 0 4 100
BGI-PUP3 192 0 2 0 1.04 0 2 100
BGI-PUP5 120 0 1 0 0.83 0 1 100
BGI-PUP6 255 0 1 0 0.39 0 1 100
N 1,269 1 4 0.08 0.32 1 3 100 75
Non-ORF 1 1
Total 29,725 42† 142† 0.13 0.46 32 100 76 70
*S and N-Sys stand for synonymous and non-synonymous substitutions, respectively. †A single substitution at the same
position in a region overlapping with two ORFs was counted as 2. The total number is 137 when such a substitution
event was counted only once so the total number of substitutions contributed by the BJ Group is reduced to 40.
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Table 5 Comparison of the Mutation Rates in SARS-CoV, Influenza Virus, and HIV*
Virus ORF Size (nt) No. of Substitute No. of non- Non-synonymous dN/dS Ka Ks Ka/Ks
substitutions rate (%) synonymous substitute
substitution rate (%)
R 21,222 92 0.43 65 0.31 2.38 0.075 0.111 0.67
S 3,768 22 0.58 13 0.35 2.00 0.108 0.188 0.57
PUP1 825 9 1.09 6 0.73 1.77 0.171 0.340 0.50
PUP2 465 5 1.08 4 0.86 4.88 0.217 0.152 1.43
E 231 1 0.43 1 0.43 0.093 0.000
SARS-CoV M 666 4 0.60 4 0.60 0.126 0.000
PUP3 192 2 1.04 2 1.04 0.492 0.000
PUP4 369 0 0.00 0 0.00 0.000 0.000
N 1,269 4 0.32 3 0.24 3.00 0.049 0.054 0.91
PUP5 297 0 0.00 0 0.00 0.000 0.000
Total 29,725 137(142) 0.46 98 0.33 2.52 0.085 0.119 0.72
HA 1,701 698 41.03 323 18.99 0.62 64.5 382.8 0.17
M2 294 98 33.33 60 20.41 0.83 178.0 815.9 0.22
M1 759 243 32.02 79 10.41 0.24 79.9 1,112 0.07
NA 1,413 418 29.58 181 12.81 0.67 12.3 69.4 0.18
Inﬂuenza NP 1,497 573 38.28 186 12.42 0.31 107.0 1,231 0.09
Virus A NS 366 128 34.97 56 15.30 0.34 90.6 1,087 0.08
PA 2,151 689 32.03 181 8.41 0.20 31.4 596.4 0.05
PB1 2,274 851 37.42 204 8.97 0.13 27.5 805.7 0.03
PB2 2,280 805 35.31 203 8.90 0.18 36.2 719.3 0.05
Total 13,638 4,784(4,803) 35.08 1,473 10.80 0.27 48.1 659.1 0.07
Gag 1,476 979 66.33 676 45.80 0.88 5,917 25,290 0.23
Pol 3,000 1,894 63.13 1,232 41.07 0.61 3,974 24,510 0.16
Vif 579 392 67.70 300 51.81 1.42 7,613 21,014 0.36
Vpr 291 202 69.42 140 48.11 0.76 5,924 28,054 0.21
HIV-1 Tat 306 216 70.59 172 56.21 2.64 11,101 16,108 0.69
Rev 303 237 78.22 189 62.38 1.70 10,107 19,080 0.53
Vpu 249 215 86.35 182 73.09 2.23 14,947 25,620 0.58
Env 2,574 1,992 77.39 1,531 59.48 1.70 10,765 23,342 0.46
Nef 624 473 75.80 370 59.29 1.12 8,632 29,346 0.29
Total 9,680 6,536(7,141) 67.52 4,792 49.50 1.15 7,445 24,094 0.31
*SARS-CoV data are from 17 isolates and referred to the notes of Table 2. Inﬂuenza Virus data are from 50 strains
of HA segment, 100 strains of M segment, 24 strains of NA segment, 88 strains of NP segment, 89 strains of NS
segment, 53 strains of PA segment, 58 strains of PB1 segment, and 58 strains of PB2 segment, downloaded from
http://www.ﬂu.lanl.gov. HIV data are from 405 strains, downloaded from http://hiv-web.lanl.gov/. Only those minor
alleles that are present in at least two sequences were considered as real substitutions.
BJ04), leading to a Gln (CAA)-to-Pro (CCA) change,
was noticed in the BJ Group speciﬁc variations. Since
it resides in the PUP2 coding sequence, the functional
signiﬁcance of such a mutation is yet to be revealed ex-
perimentally in the future. A G/A transition (Locus
25,280, A in BJ03 and BJ02, G in all others) lead-
ing to Gly/Pro (from polar to non-polar) was also
identiﬁed. These changes are not as drastic in terms
of biochemical characteristics in the amino acid com-
position as the one found within the BJ01/BJ03 pa-
tient, indicating there might be possible selection on
the latter cases. BJ04 has all the alleles at the loci
mentioned above, the same as all the other isolates,
assuring its relationship with isolates outside the BJ
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Group. GD01 shares the same alleles at three loci
with either BJ01 or BJ02, which are diﬀerent from all
the others, suggesting that these mutations are early
replication errors before the viral invasion into Bei-
jing, providing a link between the BJ Group and the
GD Group in Guangdong where the ﬁrst major epi-
demics of SARS occurred.
The sequence variation between BJ01 and BJ03
was expected to reﬂect the replication error rates,
emerging from both replication cycles and in diﬀerent
tissues inside a single host. The sequence variation
between BJ01/03 and BJ02 would reﬂect the replica-
tion errors between the ﬁrst and the second round of
the infection among the hosts, as well as the selective
pressure from the host or possible advantages taken
by the viruses. Somewhat to our surprises, we have
noticed a “square-root rule” of the non-synonymous
substitutions among the member isolates in the BJ
Group (Figure 3). There are approximately 15 to 16
Fig. 3 Two-scale substitution rates of the SARS-CoV in
the ﬁrst and second round of the transmission of the BJ
Group. The numbers above the lines that connect each
isolate are nonsynonymous substitution counts believed as
results of the ﬁrst round and second round of the trans-
mission. The numbers in the parentheses are synonymous
substitution counts between the connected isolates.
non-synonymous substitutions in the ﬁrst round of the
transmission (15 between BJ01 and BJ03, 16 between
BJ01 and BJ02, 16 between BJ01 and BJ04); it ap-
proximately equals to 42 or 24. In the second round
of the infection, there are 25 to 26 non-synonymous
substitutions (25 between BJ02 and BJ04, 25 be-
tween BJ02 and BJ03, 25 between BJ03 and BJ04);
it is close to 52, or to 25 when both non-synonymous
and synonymous substitutions are accounted. Such
a “square-root rule” implies that the mutations oc-
cur freely without any constraints from patients to
patients, perhaps due to lack of section pressure and
adaptation during early transmissions or there is not
enough time for them to become obvious, even though
there might be a slight reduce in numbers in the sec-
ond round of the infection.
We summarized the non-synonymous substitu-
tions according to their subregions deﬁned by a com-
bination of structural and/or functional properties in
the corresponding ORFs (Table 6). Data were clas-
siﬁed according to the computationally predictable
changes of physiochemical features and/or the sec-
ondary structure they would make in the correspond-
ing subregions. For example, the predicted alterations
by the substitutions of the M protein would lead to
an increased pI (isoelectric point) of the N-terminal
exterior region, decreased or increased hydrophobicity
in the TM (transmembrane) domains, and decreased
hydrophilicity in the C-terminal interior region, re-
spectively. These predictable changes should suggest
that the virus might beneﬁt from these substitutions
with remarkable changes that may be advantageous
for the virus to defend the host immune system or
drift to a new status ready for coming back. No sin-
gle base insertion or deletion has been found so far
in all the sequences published to this date; it states
clearly the ﬁdelity of the viral replication machinery.
The BJ Group as a Subset of
SARS-CoV Isolates Represents a
Discrete Viral Transmission Path
Rooted phylogenetic trees (Figures 4 and 5), pro-
posed on the basis of the haplotypes from each group,
synonymous or non-synonymous substitutions, and
the sum of all substitutions of the 17 genome se-
quences of SARS-CoV isolates from patients identi-
ﬁed in Canada, USA, Singapore, and China (Beijing,
Zhejiang, Guangdong, Hong Kong, and Taiwan), gave
diﬀerent paradigms but positioned the BJ Group, to-
gether with the newly discovered GD01 (GD-Ins29 ) in
the same clade, followed by the H-U Group, then the
H-T Group, leaving the SP Group (Singapore) more
distant. This paradigm suggests a possible transmis-
sion path from Guangdong to Beijing/Hong Kong,
then to other countries and regions. It appears con-
sistent with the epidemiological data presently avail-
able, and would suggest a possible transmission path
among Guangdong, Hong Kong, Beijing, and USA.
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Table 6 Predicted Subregional Changes by the Non-Synonymous Substitutions
in the 17 SARS-CoV Genomes
ORF Subregion Position No. of Sub- Position nt Type of Sub- Size pI Hydropho-Hydrophi- Charge Charge
(Position in ORF) (nt) stitution (a.a.) stitution (a.a.) value bicity (%) licity (%) (+)(%) (−)(%)
R LP (1-179) 246-783 4 454(70)Cys(1)/Phe(16) 179 5.4-5.5 29.1-29.6 46.4-47.5 14.0-14.5 (14.5)*
483(80)Asn(16)/Tyr(1)
489(82)Cys(1)/Gly(16)
633(130)Arg(1)/Gly(16)
p65L (180-818) 784-2,700 2 918(225)Gln(1)/Lys(16) 639 6.0-6.1 (30.2) (45.4) 12.7-12.8 (11.9)
1,161(306) Phe(1)/Val(16)
interBHID PLP 3,241-5,139 6 3,255(1,004)Asn(16)/His(1) 633 5.9-6.0 29.1-29.2 47.2-47.4 13.1-13.3 (12.5)
(999-1,631) 3,607(1,121) Ile(16)/Thr(1)
4,201(1,319)Arg(1)/Lys(16)
NSP1 4,231(1,329) Phe(16)/Ser(1)
4,957(1,538) Ser(16)/Thr(1)
4,933(1,563)Lys(1)/Met(16)
PLP 5,140-5,781 4 5,529(1,762) Ile(16)/Leu(1) 214 (7.5) 26.6-27.1 43.5-43.9 (11.7) (8.4)
(1,632-1,845) 5,572(1,776)Gln(16)/Pro(1)
5,575(1,777)Gln(16)/Pro(1)
5,662(1,806) Gly(16)/Val(1)
BHOD 5,782-6,660 2 6,129(1,962) Ile(1)/Leu(16) 293 (5.7) (27.0) (50.2) (11.9) (11.9)
(1,846-2,138) 6,593(2,116)Leu(16)/Phe(1)
interBHOD HOD1 6,661-9,180 11 6,910(2,222)Cys(16)/Tyr(1) 840 8.1-8.3 33.0-33.2 42.7-43.0 10.8-11.1 8.1-8.2
(2,139-2,978) 7,624(2,460) Pro(16)/His(1)
7,683(2,480) Ile(1)/Leu(16)
7,900(2,552) Ala(16)/Val(1)
7,911(2,556)Asn(1)/Asp(16)
7,935(2,564) Pro(1)/Ser(16)
8,368(2,708) Ser(16)/Thr(1)
8,398(2,718)Arg(16)/Thr(1)
8,553(2,770) Leu(2)/Val(15)
9,076(2,944) Ile(1)/Thr(16)
9,157(2,971) Ala(1)/Val(16)
HOD1 9,181-9,966 5 9,312(3,023) Pro(1)/Ser(16)
(2,979-3,240) 9,313(3,023) Leu(1)/Ser(16)
9,385(3,047) Ala(5)/Val(12)
9,460(3,072) Ala(2)/Val(15)
9,835(3,197) Ala(13)/Val(4)
3CLP (NSP2) 9,967-10,885 2 10,531(3,429)Gln(16)/Pro(1) 306 (6.30) (31.0) 42.8-43.1 (10.1) (8.5)
(3,241-3,546) 10,709(3,488)Asp(16)/Glu(1)
HOD2(NSP3) 10,886-11,754 2 11,472(3,743)Asn(1)/Tyr(16) 290 (8.90) (43.8) 30.7-31.0 (9.0) (3.8)
(3,547-3,836) 11,698(3,818)Asn(16)/Thr(1)
NSP4 (3,837-3,919) 11,755-12,003 2 11,952(3,903)Asn(1)/Asp(16) 83 5.2-5.7 (38.6) (50.6) (12.0) 10.8-12.0
11,955(3,904) Ile(16)/Phe(1)
NSP5 (3,920-4,117) 12,004-12,597 2 12,498(4,085) Ile(16)/Leu(1) 198 (6.30) 27.8-28.3 48.0-48.5 (11.1) (11.1)
12,499(4,085) Asn(1)/Ile(16)
NSP7 (4,231-4,369) 12,939-13,353 4 12,963(4,240) Asn(16)/His(1) 139 5.9-6.4 (22.3) (40.3) 8.6-10.1 (7.9)
12,975(4,244) Ile(1)/Leu(16)
13,006(4,254) Ala(16)/Gly(1)
13,008(4,255)Gln(1)/Lys(16)
RdRp(NSP9) 13,354-16,149 4 13,475(4,411) Ile(1)/Val(16) 932 6.0-6.1 30.3-30.5 44.4-44.6 (12.9) 11.5-11.6
(4,370-5,301) 13,476(4,411) Gly(1)/Val(16)
14,019(4,592) Glu(1)/Val(16)
14,973(4,910)Gln(16)/Leu(1)
HEL (NSP10) 16,150-17,952 3 17,112(5,623) Leu(16)/Ser(1) 601 8.5-8.6 27.6-27.8 44.1-44.4 12.5-12.6 (8.7)
(5,302-5,902) 17,474(5,744)Arg(16)/Cys(1)
17,545(5,767)Asp(11)/Glu(6)
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Table 6 (Continued)
ORF Subregion Position No. of Sub- Position nt Type of Sub- Size pI Hydropho-Hydrophi- Charge Charge
(Position in ORF) (nt) stitution (a.a.) stitution (a.a.) value bicity (%) licity (%) (+)(%) (−)(%)
NSP11 17,953-19,533 2 18,263(6,007) Ile(1)/Leu(16) 527 (7.5) 30.4-30.6 43.6-43.8 (13.9) (9.7)
(5,903-6,429) 19,065(6,274) Ile(4)/Thr(13)
NSP12 19,534-20,571 2 20,344(6,700) Ile(1)/Met(16) 346 (5.1) (32.9) (46.2) (11.8) (13.3)
(6,430-6,775) 20,429(6,729)Asn(1)/Asp(16)
NSP13 20,572-21,465 7 20,762(6,840)Leu(1)/Met(16) 298 7.3-7.5 (32.9) 44.4-44.6 11.1-11.4 (9.1)
(6,776-7,073) 20,829(6,862)Gln(16)/Pro(1)
20,875(6,877)Asp(16)/Glu(1)
21,053(6,937) Ala(16)/Pro(1)
21,200(6,992)Asp(1)/Glu(16)
21,268(7,008)Asn(16)/Lys(1)
21,314(7,024)Gln(1)/Lys(16)
S Region 3 21,650-21,815 1 21,702(77) Asp(5)/Gly(12) 56 7.9-9.0 (33.9) 44.6-46.4 (10.7) 3.6-5.4
(60-115)
Region 4 21,815-21,905 1 21,902(144) Leu(1)/Met(16) 31 (5.8) (38.7) (38.7) (6.5) (6.5)
(115-145)
Region 7 22,130-22,235 2 22,188(239) Leu(1)/Ser(16) 36 (8.0) 33.3-36.1 30.6-33.3 (5.6) (2.8)
(220-255) 22,203(244) Ile(11)/Thu(6)
Region 8 22,235-22,430 1 22,403(311) Arg(2)/Gly(15) 66 5.1-6.0 (28.8) 48.5-50.0 10.6-12.1 (12.1)
(255-320)
Region 14 23,150-23,210 1 23,201(577) Ala(1)/Ser(16) 21 (4.3) (23.8) 47.6-52.4 (9.5) (19.0)
(560-580)
Region 20 23,960-24,110 2 24,050(860) Leu(1)/Val(16) 51 4.1-4.6 (33.3) (27.5) 2.0-3.9 (5.9)
(830-880) 24,053(861) Arg(1)/Ser(16)
Region 24 24,395-24,500 1 24,474(1,001)Arg(16)/Met(1) 36 9.7-10.8 27.8-30.6 47.2-50.0 11.1-13.9 (5.6)
(975-1,010)
BGI-(1-274) 25,249-26,073 6 25,279(11) Arg(1)/Gly(16) 274 5.4-5.8 34.7-35.0 39.1-39.4 8.0-8.8 7.7-8.4
PUP1 25,280(11) Glu(2)/Gly(15)
25,550(101) Lys(1)/Met(16)
25,654(136) Gln(2)/Lys(15)
25,760(171) Ala(1)/Glu(16)
25,825(193) Arg(16)/Trp(1)
BGI-(1-154) 25,670-26,134 4 25,760(31) Gln(1)/Lys(16) 154 9.9-10.9 37.0-40.1 51.9-52.3 18.8 0.60-0.62
PUP2 25,965(99) Ile(1)/Thr(16)
26,013(115) Gln(1)/Leu(16)
26,031(121) Gln(15)/Pro(2)
E (1-76) 26,098-26,328 1 26,167(24) Met(1)/Val(16) 76 (6.0) (47.4) (32.9) (5.3) (5.3)
Exterior 26,379-26,433 1 26,409(11) Glu(16)/Lys(1) 18 4.2-4.8 (33.3) (55.6) 5.6-11.116.7-22.2
(1-18)
M TM I (19-37) 26,434-26,487 1 26,458(27) Cys(1)/Phe(16) 18 (5.6) 68.4-73.7 (10.5) (0.0) (0.0)
TM II(50-72) 26,529-26,585 1 26,581(68) Ala(16)/Val(1) 22 (7.9) 63.6-68.2 (9.1) (4.5) (0.0)
Interior 26,676-27,044 1 26,838(154) Pro(1)/Ser(16) 122 (9.8) (30.9) 44.7-45.5 (15.4) (7.3)
(99-221)
BGI-(1-63) 27,055-27,246 2 27,092(13) Glu(16)/Gly(1) 63 4.7-4.8 46.0-47.6 41.3-42.9 (11.1) 14.3-15.9
PUP3 27,224(57) Leu(5)/Pro(12)
N Region 7 28,509-28,634 2 28,519(140) Leu(16)/Trp(1) 42 7.9-8.0 14.3-16.7 47.6-52.4 (16.7) (5.6)
(137-178) 28,560(154) Asn(16)/Tyr(1)
Region 8 28,635-28,769 1 28,677(193) Cys(1)/Gly(16) 45 12.0-12.1 (8.9) (57.8) (13.3) (2.2)
(179-223)
*Numbers in the parentheses for the last ﬁve columns indicate the percentage of the parameters that are not aﬀected
by the amino acid changes.
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Fig. 4 A rooted phylogenetic tree (GD01 as the postulated root) indicates the deﬁned haplotypes and possible
transmission path of the SARS-CoV based on the complete genome sequences of 17 SARS-CoV isolates. The neighbor-
joining trees are generated by using the program Clustalw 1.81. The sources and abbreviations of the sequences are
referred to Table 2.
Fig. 5A (all substitutions)
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Fig. 5B (haplotypes)
Fig. 5C (non-synonymous)
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Fig. 5D (synonymous)
Fig. 5 Proposed rooted phylogenetic trees of the 17 isolates of the SARS-CoV based on all substitutions (A), haplotypes
(B), non-synonymous (C), and synonymous (D) substitutions.
It is obvious that we are just in the early process of
exploiting the information from the genomes of SARS-
CoV isolates from patients of diﬀerent countries and
regions. The ﬁnal picture of the infection route and
the mutation spectra will be revealed in due time as
long as we keep sequencing the many clinical isolates
of the virus accurately and consistently. We have been
doing so since the epidemic started, ﬁnding the unique
insertion variant in the samples from Guangdong and
now the haplotypes, and we will keep doing so until
the next round of the infection if it does come in this
fall.
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